Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Foscarnet Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,652Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of October 25, 2023
    Enforcement Report - Week of October 25, 2023

    25 Oct 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf

    FDA
    25 Oct 2023
    Share Share
    Avet's Generic Foscarnet Sodium Receives Approval in the U.S.
    Avet's Generic Foscarnet Sodium Receives Approval in the U.S.

    05 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213807

    FDA
    05 Jun 2023
    Share Share
    Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older
    Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older

    02 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211202005653/en

    BUSINESSWIRE
    02 Dec 2021
    Share Share
    Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more
    Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more

    23 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211123006185/en

    BUSINESSWIRE
    23 Nov 2021
    Share Share
    FDA's ADAC unanimously backs Takeda's drug for post-transplant cytomegalovirus
    FDA's ADAC unanimously backs Takeda's drug for post-transplant cytomegalovirus

    08 Oct 2021

    // Z. Brennan ENDPTS

    https://endpts.com/fdas-antimicrobial-adcomm-unanimously-backs-takedas-drug-for-post-transplant-cytomegalovirus/

    Z. Brennan ENDPTS
    08 Oct 2021
    Share Share
    Phase 3 Trial Subgroup Analysis Across SOT Types Supports Efficacy of Maribavir
    Phase 3 Trial Subgroup Analysis Across SOT Types Supports Efficacy of Maribavir

    07 Jun 2021

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2021/phase-3-clinical-trial-subgroup-analysis-across-sot-types-supports-efficacy-of-maribavir-over-conventional-therapies-in-post-transplant-recipients-with-cmv-infection/

    PRESS RELEASE
    07 Jun 2021
    Share Share